- Product
- Government likely to list Zejula in December
- by Byun Kyung A Oct 31, 2019 09:36am
- Sources predict Zejula, an ovarian cancer treatment, would get listed for healthcare reimbursement in coming December. According to an industry insider on Oct. 16, Takeda Pharmaceuticals Korea is waiting for Health Insurance Policy Deliberation Committee’s (HIPDC) deliberation, after recently reaching an agreement with National Health
- Product
- Listing first-line lung cancer treatment Tagrisso 'deferred'
- by Byun Kyung A Oct 31, 2019 09:35am
- A first-line anticancer therapy, Tagrisso could struggle to get listed for NHI reimbursement. An industry insider reported on Oct. 17, Health Insurance Review and Assessment Service (HIRA) Cancer Disease Deliberation Committee decided to ‘defer’ on the decision to list Tagrisso (osimertinib), a third generation Epidermal Growth Factor
- Policy
- For reimbursed drug, efficacy and cost-efficiency come first
- by Byun Kyung A Oct 31, 2019 09:34am
- On the last day of the 20th National Assembly Annual Audit for the Health Insurance Review and Assessment Service (HIRA), half the questions were dedicated to pharmaceutical affairs. The lawmakers of the NA Health and Welfare Committee questioned HIRA about NHI reimbursement reevaluation on dementia treatment choline alfoscerate, reimbu
